中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Causes of death after transjugular intrahepatic portosystemic shunt in patients with hepatic sinusoidal obstruction syndrome

DOI: 10.3969/j.issn.1001-5256.2020.12.022
Research funding:

 

  • Received Date: 2020-07-01
  • Published Date: 2020-12-20
  • Objective To investigate the clinical features and causes of death after transjugular intrahepatic portosystemic shunt( TIPS) in patients with hepatic sinus obstruction syndrome( HSOS),as well as the prevention and treatment measures to further improve the survival rate of such patients. Methods A retrospective analysis was performed for 293 patients with HSOS who were admitted to Nanjing Drum Tower Hospital from January 2013 to December 2019,among whom 20 patients died after TIPS. General information,laboratory examination,and clinical treatment regimen were analyzed,and clinical indices and complications were compared at different stages of the disease.The paired t-test was used for comparison of normally distributed continuous data between groups,and the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between groups. Results The mean survival time was 15. 15 ± 4. 21 weeks for the 20 patients who died,among whom there were 15 male patients and 5 female patients,with a mean age of 67. 60 ± 7. 01 years;there were 17 patients( 85%) aged ≥60 years,and more than 90% of the patients had abdominal distention and oliguria. Among the 20 patients who died,9( 45%) had chronic underlying diseases,and 5( 25%) had more than two underlying diseases. Portal venous pressure decreased from 21. 67 ± 5. 15 mm Hg before surgery to 8. 17 ± 4. 98 mm Hg after surgery( t = 10. 318,P < 0. 05). The levels of total bilirubin,direct bilirubin,and D-dimer were significantly higher than the normal values before surgery,and there were significant increases in these levels on day 5 after surgery( Z = 3. 823,3. 823,2. 756,all P < 0. 05); the hemoglobin level,platelet count,and creatinine level tended to decrease on day 5 after surgery( t = 4. 979,t = 2. 147,Z =-3. 125,all P < 0. 05). Three patients had hepatic encephalopathy before surgery,while 10 patients( 50%) had hepatic encephalopathy after surgery. Causes of death included acute liver failure,infectious shock,and multiple organ failure syndrome( MODS). Conclusion The possible risk factors for death after TIPS in HSOS patients include underly-ing diseases,high bilirubin,and complications such as hepatic encephalopathy and renal dysfunction. Causes of death mainly include acute liver failure and MODS. Ultrasound and laboratory markers should be reexamined during anticoagulation therapy to identify the patients with progression to severe diseases as early as possible,and in case of progressive deterioration of indices,TIPS should be selected as early as possible to improve the survival rate and prognosis of such patients. In addition,hemobilia should be observed during and after surgery,and intervention measures should be adopted in time to further reduce mortality rate.

     

  • [1] ZHUGE Y,LIU Y,XIE W,et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol,2019,34(4):634-642.
    [2] YANG XQ,YE J,LI X,et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:Pathogenesis,clinical manifestations,diagnosis,treatment,and outcomes[J].World J Gastroenterol,2019,25(28):3753-3763.
    [3] DELEVE LD,SHULMAN HM,McDONALD GB. Toxic injury to hepatic sinusoids:Sinusoidal obstruction syndrome(veno-occlusive disease)[J]. Semin Liver Dis,2002,22(1):27-42.
    [4] Cooperative Group for Hepatic and Gall Diseases,Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome(2017,Nanjing)[J]. J Clin Hepatol,2017,33(9):1627-1637.(in Chinese)中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J].临床肝胆病杂志,2017,33(9):1627-1637.
    [5] BOYER TD. Transjugular intrahepatic portosystemic shunt:Current status[J]. Gastroenterology,2003,124(6):1700-1710.
    [6] LIU ZL,FAN ZP,GOU YS,et al. Clinical features,pathogenesis,and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol,2019,35(1):208-212.(in Chinese)刘贞利,范作鹏,勾钰淞,等.不同类型肝窦阻塞综合征的临床特征、发病机制与诊治[J].临床肝胆病杂志,2019,35(1):208-212.
    [7] ROEKER LE,KIM HT,GLOTZBECKER B,et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation[J]. Biol Blood Marrow Transplant,2019,25(1):137-144.
    [8] GAO H,LI N,WANG JY,et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids[J]. J Dig Dis,2012,13(1):33-39.
    [9] CRAWFORD MJ. Vascular disorders of the liver[J]. Clin Liver Dis,2010,14(4):635-650.
    [10] LIN G,WANG JY,LI N,et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum[J]. J Hepatol,2011,54(4):666-673.
    [11] ZHUGE YZ,WANG Y,ZHANG F,et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int,2018,38(10):1867-1874.
    [12] CHOJKIER M. Hepatic sinusoidal-obstruction syndrome:Toxicity of pyrrolizidine alkaloids[J]. J Hepatol,2003,39(3):437-446.
    [13] CORBACIOGLU S,CESARO S,FARACI M,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation:An open-label,phase 3,randomised controlled trial[J]. Lancet,2012,379(9823):1301-1309.
    [14] PENG C,ZHANG X,ZHANG F,et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome:A retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol,2020,32(9):1168-1178.
    [15] WANG Y,QIAO D,LI Y,et al. Risk factors for hepatic venoocclusive disease caused by Gynura segetum:A retrospective study[J]. BMC Gastroenterol,2018,18(1):156.
  • Cited by

    Periodical cited type(3)

    1. 袁世轩,吕子彦,杨勇,陈璐,张丽娟. 模型引导下的万古霉素血药浓度监测临床研究. 中国临床药理学与治疗学. 2024(12): 1344-1352 .
    2. 林华骏,冯哲文,辛城霖,管成剑,张小东,闵逸洋,顾晓哲,郭伟,汪栋. 术前胆道引流对胰十二指肠切除术后手术相关并发症发生的影响因素分析. 中华消化外科杂志. 2023(07): 909-915 .
    3. 黄燕茹,何南凤,郑巧梅. 安全预警管理干预联合抗菌药物在儿童胆总管囊肿术后的应用观察. 北方药学. 2022(07): 186-188 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4462) PDF downloads(85) Cited by(4)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return